Allergy Therapeutics Plc has appointed Pieter-Jan de Kam as clinical director to lead development of the company’s portfolio of products for allergic disorders. Also joining the UK company is Simon Piggott as of head of clinical science.
Dr de Kam joins the company from the HAL Allergy Group in the Netherlands where he was head of clinical development and pharmacovigilance. Before that, he directed clinical research at Merck & Co Inc in the US and Singapore. Dr de Kam holds a PhD in clinical pharmacology and a master of business administration from the University of Groningen in the Netherlands.
Allergy Therapeutics recruited Dr Piggott from Quintiles/IMS, the global clinical research and information technology company. The executive also previously worked at Vertex Pharmaceuticals Inc and GlaxoSmithKline Plc.
Allergy Therapeutics announced the appointments on 11 September 2017.
Copyright 2017 Evernow Publishing Ltd